Authors:
and
Amruta S. Khurd
amrutakhurd@rediffmail.com
Amruta S. Khurd
Department of Pharmaceutical Chemistry, Sinhgad Technical Education Society Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India
Search for other papers by Amruta S. Khurd in
Current site
Google Scholar
PubMed
Search for other papers by Amruta S. Khurd in
Current site
Google Scholar
PubMed
Kajal V. Doshi
Kajal V. Doshi
Department of Pharmaceutical Chemistry, Sinhgad Technical Education Society Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India
Search for other papers by Kajal V. Doshi in
Current site
Google Scholar
PubMed
Search for other papers by Kajal V. Doshi in
Current site
Google Scholar
PubMed
Summary
The objective of this study was to develop a new rapid and robust high-performance thin-layer chromatographic (HPTLC) method for the estimation of rivaroxaban (RRB) in tablet dosage form using a quality by design approach. Chromatography was performed using a pre-coated silica gel aluminum plate 60 F254 (10 cm × 10 cm) as the stationary phase and toluene–methanol (7:3, V/V) as the mobile phase. Detection was carried out at 250 nm. The linear regression analysis data for the calibration plots showed r2 > 0.99 with a concentration range from 100–600 ng per band. A Box-Behnken experimental design with a response surface methodology was applied to study the effects of chamber saturation time, band length, and solvent front on the RF value and area of RRB. The RF value was predicted to be 0.63 ± 0.05 for RRB to optimize the chromatographic conditions based on the preliminary trials. The optimized HPTLC method was validated according to the International Conference on Harmonization (ICH) guideline Q2 (R1). The results of this study indicate that the quality by design (QbD) concept could be effectively applied to optimize a HPTLC method with a minimum number of experimental runs. The developed HPTLC method was successfully applied for routine analysis of RRB in tablet dosage form.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
[1]
K. Chandra , P. Satya, A. Dhana, C. Anupama, N. Devanaboyina, A new method for development and validation for analysis of rivaroxaban in formulation by RP-HPLC, Res. Desk. 1 (2012) 24–33.
-
[2]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines, Q1A (R2) (2003): Stability Testing of New Drug Substances and Products, Geneva, 2005, 1–24.
-
[3]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use Guidelines, Q2 (R1) (2005): Validation of Analytical Procedures, Geneva, 2005, 1–17.
-
[4]
I. Lories , A. Mostafa, M. Girges, High performance liquid chromatography, TLC densitometry, first derivative and first derivative ratio spectrophotometry for determination of rivaroxaban and its alkaline degradates in bulk powder and its tablets, J. Chromatogr. Sep. Tech. 4 (2013) 202–2010.
-
[5]
A. Mohamed , A. Medhat, Al-Ghobashy, M. Hayam, Investigation of the profile and kinetics of degradation of rivaroxaban using HPLC, TLC-densitometry and LC-MS/MS: application to pre-formulation studies, Bull. Fac. Pharm. (Cairo Univ). 53 (2015) 53–61.
-
[6]
E. Perzborn , S. Roehrig, A. Straub, D. Kubitza, W. Mueck, V. Laux, A new oral factor Xa inhibitor, Arter. Thromb. Vasc. Biol. 30 (2010) 376–381.
-
[7]
S. Roehrig , A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer, K. Schlemmer, P. Reinemer, E. Perzborn, Discovery of the novel antithrombotic agent 5-chloro-N-({(5 S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor, J. Med. Chem. 48 (2005) 5900–5908.
-
[8]
P. Sadanshio , S. Wankhede, P. Chaudhari, Validated stability indicating HPTLC method for estimation of ribavirin in capsule in presence of its alkaline hydrolysis degradation product, Anal. Chem. Lett. 4 (2014) 343–358.
-
[9]
C. Sekaran , V. Bind, M. Damayanthi, A. Sireesha, Development and validation of UV spectrophotometric method for the determination of rivaroxaban, Der Pharma Chem. 5 (2013) 1–5.
-
[10]
B. Seshamamba , P. Venkata, Application of stability indicating HPLC method with UV detector to the analysis of rivaroxaban in bulk and tablet dosage form, Chem. Sci. Trans. 10 (2014) 893–899.
-
[11]
A. Thomas , S. Patil, R. Nanda, L. Kothapalli, S. Bhosle, A. Deshpande, Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form, Saudi Pharm. J. 19 (2011) 221–231.
-
[12]
D. Vaghela , P. Patel, High performance thin layer chromatographic method with densitometry analysis for determination of rivaroxaban from its tablet dosage form, Int. J. Pharm. Pharm. Sci. 6 (2014) 123–128.
To see the editorial board, please visit the website of Springer Nature.
Manuscript Submission: HERE
For subscription options, please visit the website of Springer Nature.
| Journal of Planar Chromatography - Modern TLC | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1988 |
| Volumes per Year |
1 |
| Issues per Year |
6 |
| Founder | Akadémiai Kiadó |
| Founder's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Publisher | Akadémiai Kiadó Springer Nature Switzerland AG |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. CH-6330 Cham, Switzerland Gewerbestrasse 11. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 0933-4173 (Print) |
| ISSN | 1789-0993 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 20 | 0 | 0 |
| Jul 2024 | 13 | 0 | 0 |
| Aug 2024 | 27 | 0 | 0 |
| Sep 2024 | 61 | 0 | 0 |
| Oct 2024 | 116 | 0 | 0 |
| Nov 2024 | 143 | 0 | 0 |
| Dec 2024 | 127 | 0 | 0 |
Author:
Authors:
, , , , , and
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory